Humacyte Company Insiders
| HUMAW Stock | USD 1.69 0.11 6.96% |
Humacyte employs about 183 people. The company is managed by 12 executives with a total tenure of roughly 427 years, averaging almost 35.0 years of service per executive, having 15.25 employees per reported executive. Recap of Humacyte's management performance can provide insight into the venture performance.
Humacyte |
Humacyte Management Team Effectiveness
The company has return on total asset (ROA) of (0.5323) % which means that it has lost $0.5323 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (8.5081) %, meaning that it generated substantial loss on money invested by shareholders. Humacyte's management efficiency ratios could be used to measure how well Humacyte manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to climb to -0.82 in 2024. Return On Capital Employed is likely to drop to -0.96 in 2024. At this time, Humacyte's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to climb to about 46.6 M in 2024, despite the fact that Return On Tangible Assets are likely to grow to (0.82).Common Stock Shares Outstanding is likely to drop to about 61.4 M in 2024
Humacyte Workforce Comparison
Humacyte is rated # 3 in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 1,279. Humacyte retains roughly 183 in number of employees claiming about 14% of equities under Health Care industry.
Humacyte Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Humacyte insiders, such as employees or executives, is commonly permitted as long as it does not rely on Humacyte's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Humacyte insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Niklason Laura E over three months ago Disposition of 2625000 shares by Niklason Laura E of Humacyte at 2.75 subject to Rule 16b-3 | ||
Heather Prichard over three months ago Acquisition by Heather Prichard of 136000 shares of Humacyte subject to Rule 16b-3 | ||
Wallace Max N. over six months ago Disposition of 6564 shares by Wallace Max N. of Humacyte at 1.19 subject to Rule 16b-3 | ||
Heather Prichard over six months ago Disposition of 6564 shares by Heather Prichard of Humacyte subject to Rule 16b-3 |
Humacyte Notable Stakeholders
A Humacyte stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Humacyte often face trade-offs trying to please all of them. Humacyte's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Humacyte's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Juliana Blum | CoFounder Advisor | Profile | |
| Harold Alterson | Senior Quality | Profile | |
| MS MS | Chief Officer | Profile | |
| Sabrina Osborne | Executive People | Profile | |
| Kiernan MD | Chief Officer | Profile | |
| Dale Sander | Chief CFO | Profile | |
| William Scheessele | Chief Officer | Profile | |
| Yang MD | Chief Officer | Profile | |
| B Scheessele | Chief Officer | Profile | |
| Shamik MD | Chief Officer | Profile | |
| SPHR GPHR | Chief Officer | Profile | |
| Heather Prichard | Chief Officer | Profile |
About Humacyte Management Performance
The success or failure of an entity such as Humacyte often depends on how effective the management is. Humacyte management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Humacyte management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Humacyte management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.86) | (0.82) | |
| Return On Capital Employed | (0.91) | (0.96) | |
| Return On Assets | (0.86) | (0.82) | |
| Return On Equity | (8.18) | (7.77) |
Please note, the imprecision that can be found in Humacyte's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Humacyte. Check Humacyte's Beneish M Score to see the likelihood of Humacyte's management manipulating its earnings.
Humacyte Workforce Analysis
Traditionally, organizations such as Humacyte use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Humacyte within its industry.Humacyte Manpower Efficiency
Return on Humacyte Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 605.3K | |
| Net Loss Per Executive | 9.2M | |
| Working Capital Per Employee | 354.3K | |
| Working Capital Per Executive | 5.4M |
Additional Tools for Humacyte Stock Analysis
When running Humacyte's price analysis, check to measure Humacyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Humacyte is operating at the current time. Most of Humacyte's value examination focuses on studying past and present price action to predict the probability of Humacyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Humacyte's price. Additionally, you may evaluate how the addition of Humacyte to your portfolios can decrease your overall portfolio volatility.